# GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

> **NCT04387201** · PHASE4 · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 23 (actual)

## Conditions studied

- Glucose Intolerance
- Overweight and Obesity
- Drug Effect
- Adiposity

## Interventions

- **DRUG:** Cyanocobalamin
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT04387201
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-15
- **Primary completion:** 2023-10-06
- **Final completion:** 2023-10-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04387201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04387201, "GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04387201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*